Holen Sie sich die Stockscreener-App
121.51
4.01%
4.69
Handel nachbörslich:
122.67
1.16
+0.95%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Top Research Reports for Mastercard, AstraZeneca & Sandisk - Zacks Investment Research
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Halozyme director Matthew Posard sells $567,660 of common stock - Investing.com
Form 4 Halozyme Therapeutics Inc: Matthew L. Posard (Director) For: 1 October - Investing.com Canada
Form 4 Halozyme Therapeutics Inc: Matthew L. Posard (Director) For: 1 October - Investing.com India
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability - ChartMill
Halozyme Therapeutics Insider Sold Shares Worth $6,610,501, According to a Recent SEC Filing - www.marketscreener.com
Form 4 Halozyme Therapeutics Inc For: 8 October By Investing.com - Investing.com Nigeria
HALO Maintained by JP Morgan -- Price Target Raised to $78.00 - GuruFocus
A director received 3,796 stock units at Halozyme (HALO), not the 6,796 originally reported. - Stock Titan
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
HALO Maintains Buy Rating -- Price Target Raised to $130 by HC Wainwright - GuruFocus
Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? - Yahoo! Finance Canada
Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? - Yahoo Finance
Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock. - Barron's
Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme stock rises after winning injunction against Merck - Yahoo Finance
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - TradingView
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets - PR Newswire
HALOThe $300+ Runway: Why Halozyme’s Pipeline Transition Erases the Patent Cliff - Simply Wall Street
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Singapore
A drug-delivery partnership expands from six exclusive targets to eight. - Stock Titan
Halozyme Therapeutics, Inc. And Argenx Announce Expansion Of Global Collaboration And License Agreement To Support The Development Of Subcutaneous Formulations For Two Additional Exclusive Targets Using ENHANZE® Technology - www.marketscreener.com
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology - PR Newswire
Halozyme Therapeutics, Inc. - Simply Wall Street
Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup - ChartMill
Director Daly’s 1,169-unit stock grant at Halozyme (HALO) is scheduled to vest at the 2027 annual meeting. - Stock Titan
Halozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC Filing - marketscreener.com
[Form 3] HALOZYME THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Under a trading plan, director Matthew L. Posard sells 5,230 Halozyme (HALO) shares. - Stock Titan
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo! Finance Canada
Halozyme appoints Jim Daly to board of directors By Investing.com - Investing.com Nigeria
Halozyme Announces Appointment of Jim Daly to its Board of Directors - PR Newswire
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors - marketscreener.com
Price to cash flow ratio of Halozyme Therapeutics, Inc. – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Australia
Halozyme Therapeutics, Inc. Revenue Breakdown – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) - TradingView
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo! Finance Canada
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
2.28%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):